Dudediligence.

Aclaris Therapeutics, Inc

ACRSNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$4.3MSep ’24$9.2MDec ’24$1.5MMar ’25$1.8MJun ’25$3.3MSep ’25$1.3MDec ’25$2.0MMar ’26$1.6MJun ’26
Net income, by quarter
−$7.6MSep ’24−$96.6MDec ’24−$15.1MMar ’25−$15.4MJun ’25−$14.6MSep ’25−$19.8MDec ’25−$19.8MMar ’26−$21.5MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$6.8M$29.8M$31.2M$18.7M$7.8M
Gross profit$2.0M$25.7M$27.8M$15.9M$5.7M
Operating income−$89.7M−$89.9M−$97.4M−$141.9M−$76.4M
Net income−$90.9M−$86.9M−$88.5M−$132.1M−$64.9M
Operating cash flow−$52.1M−$67.6M−$78.3M−$20.1M−$47.1M
Free cash flow−$52.4M−$68.2M−$79.6M−$20.2M−$47.2M
Cash$27.3M$45.3M$39.9M$24.6M$20.0M
Shares outstanding61.2M66.7M70.9M107.9M120.5M